Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield Texas Drug List Coverage | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - TexasPolicy N/A

    2025 Drug List (Pharmacy Benefit) — Formulary and Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Texas policy alerts

    Know when Blue Cross Blue Shield - Texas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs the pharmacy drug list for Blue Cross and Blue Shield of Texas members, describing covered drugs, tiers, specialty drug handling, and processes for exceptions, prior authorization, step therapy, and limits. Affects members, prescribing providers, pharmacies, and specialty pharmacy partners.

    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    Policy2025 Drug List (Pharmacy Benefit) — Formulary and Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests and supporting documentation for drugs annotated with 'PA' before dispensing to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~120drug lines in extract
    QLfrequent requirement
    PAPA appears for many agents
    MyPrime.com / bcbstx.comreference sites
    Accredospecialty contact

    Coverage framework and per-product criteria

    Pharmacy Coverage Framework

    Covered when ALL of the following are met:

    Drug listed on the Drug List: The medication is included on the payer's Drug List (formulary) for the member's plan.

    Drugs not shown on the Drug List are not covered under the pharmacy benefit; see plan materials for exceptions.

    Benefit plan terms: Use is consistent with the member's benefit plan (tier placement determines member cost-share).

    Tier flags include Preferred Generic (p), Non‑Preferred Generic (np), Preferred Brand (P), Non‑Preferred Brand (NP), Preferred Specialty, Non‑Preferred Specialty; check MyPrime.com or bcbstx.com for plan-specific tiering.

    Administrative requirements satisfied: Any Requirements/Limits shown for the product (PA, QL, SP, ST, AC) have been met and any required prior authorization or specialty routing has been obtained prior to dispensing.

    Prior authorization must be approved before coverage where 'PA' is indicated; failure to obtain PA or adhere to QL may result in denial.

    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    Policy2025 Drug List (Pharmacy Benefit) — Formulary and Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests and supporting documentation for drugs annotated with 'PA' before dispensing to avoid claim denial.
    SourceLink
    On This Page
    Coverage framework and per-product criteriaFormulary listings and code tablesPrior authorization, step therapy, documentation and denial risksStep therapy flags and program notesCommon quantity limits (QL) and product examplesAdditional QL product examplesWhere drugs are covered (medical vs pharmacy vs specialty)Terms and abbreviations used in the formularyContext and scopePolicy revision timeline
    Quantity/dispensing limits adhered to: Requested quantity and day‑supply do not exceed the product's listed quantity limits (QL) or supply restrictions.

    Common QL formats include e.g., 30 tablets/30 days, 100 mL/30 days for insulin, or pack/180 days for titration kits; see specific product line for numeric QL.

    Formulary coverage entries (product-specific requirements)

    Covered when the following product‑level requirements are met:

    Product on formulary excerpt: The specific product presentation (drug, strength, formulation) appears on the Drug List with a Drug Tier assignment.

    Formulary entries include Special Requirements (e.g., PA, QL, SP) that govern coverage.

    Prior authorization when indicated: If the product's Requirements/Limits include 'PA', a prior authorization must be submitted and approved before coverage.

    Examples in the listing: EPCLUSA shows Requirements/Limits = PA.

    Quantity limits when indicated: If the product line lists a QL value, the dispensed quantity and the time interval must be within that limit (or an override must be approved).QL (as listed per product)

    Example: QL (30 tablets/30 days) applies to some antiretroviral entries.

    Hepatitis C agents — DAA agents listed with PA and specialty flags on selected products

    Direct‑acting antivirals for hepatitis C are covered when ALL of the following are met:

    Formulary inclusion: The DAA regimen (specific product/packaging) is listed on the Drug List for the member's plan.

    Products such as MAVYRET and EPCLUSA appear on the list with tier assignments.

    Prior authorization obtained when required: A prior authorization is submitted and approved when the product's Requirements/Limits include 'PA'.

    EPCLUSA, HARVONI, MAVYRET, SOVALDI and VOSEVI are shown with PA flags in the formulary.

    Specialty handling when required: If the product is marked 'SP' the medication is dispensed via the plan's specialty pharmacy program as required.

    Many hepatitis DAAs include 'SP' in Requirements/Limits.

    Adherence to product QL: Any listed QL (e.g., 30 tablets/30 days or 28 tablets/28 days for pellet packs) must be followed or an approved override documented.QL (30 tablets/30 days or 28 tablets/28 days as listed)

    EPCLUSA examples: QL (30 tablets/30 days) for tablets; QL (28 tablets/28 days) for pellet pack.

    Vaccine coverage notes

    Vaccines are covered when the listed administrative criteria are satisfied:

    Formulary vaccine listing: The vaccine formulation and season/year (if specified) appear on the Drug List.

    Examples include COMIRNATY 2024-25 and AFLURIA 2024-2026 listings.

    Administrative coverage / criteria (AC): If the product line lists 'Requirements/Limits = AC' the payer's administrative criteria must be met and any required documentation submitted.

    Many vaccine entries (COMIRNATY, AREXVY, AFLURIA, BEXSERO, CAPVAXIVE) are annotated with AC.

    Contraceptives / Progestins

    Contraceptives and progestin products are covered when ALL of the following are met:

    Formulary presence and tier: The specific contraceptive product/strength/formulation is listed on the Drug List with a Drug Tier assignment.

    Tier and Requirements/Limits determine coverage and member cost-share.

    Administrative controls and prior authorization: When Requirements/Limits include 'AC' or 'PA' the required documentation and prior authorization must be submitted and approved prior to coverage.

    Several combined oral contraceptives and emergency contraception (ELLA) show AC and some lines include PA.

    Quantity limits respected: Dispensing is within the product's listed QL (for many oral contraceptives QL = 28 tablets/21 days; for ELLA QL = 2 tablets/365 days; for rings/devices QL often 1 ring/365 days or 1 ring/21 days as listed).QL (product-specific e.g., 28 tablets/21 days; 2 tablets/365 days)

    Examples: combined oral contraceptives QL (28 tablets/21 days); ELLA QL (2 tablets/365 days); NUVARING QL (1 ring/21 days).

    Antidiabetics / GLP-1 / GIP agents

    GLP‑1, GIP/GLP‑1 and other antidiabetic agents are covered when ALL of the following are met:

    Product listed on formulary: The antidiabetic product (oral or injectable) appears on the Drug List for the member's plan.

    Examples include FARXIGA, GLYXAMBI, JARDIANCE, MOUNJARO, OZEMPIC, TRULICITY in the listing.

    Prior authorization when required: If the product's Requirements/Limits include 'PA', a prior authorization must be submitted and approved prior to coverage.

    Many GLP‑1/GIP agents are annotated with PA in formulary entries.

    Quantity/supply limits adhered to: Dispensing must comply with any QL or supply limits shown (examples include QL (30 tablets/30 days) for many oral antidiabetics or pen supply limits such as QL (4 pens/28 days) for some injectables).QL (product-specific, e.g., 30 tablets/30 days; 4 pens/28 days)

    MOUNJARO, OZEMPIC, TRULICITY examples: MOUNJARO PA, QL (4 pens/28 days); OZEMPIC PA, QL (1 pen/28 days); TRULICITY PA, QL (4 pens/28 days).

    Rapid-acting Insulin

    Rapid‑acting insulins and insulin pens/cartridges are covered when ALL of the following are met:

    Formulary listing: The specific rapid‑acting insulin product (pen, cartridge, vial) is listed on the Drug List.

    Examples include FIASP, HUMALOG, NOVOLOG, LYUMJEV entries.

    Quantity limit enforced: Dispensing does not exceed the product's QL, typically QL (100 mls/30 days) for many rapid‑acting and other insulin presentations.QL (100 mls/30 days)

    Pen and cartridge formats are included under the same volume QL in the listings.

    Formulary coverage entries — Insulin and related endocrine drugs

    Coverage and utilization controls for insulin and related endocrine products:

    Product‑level tiering and limits: Each insulin or endocrine product line shows a Drug Tier and, where specified, Requirements/Limits such as PA, QL, SP that must be followed.

    This formulary segment lists multiple insulin formulations and associated QLs (commonly 100 mL/30 days).

    Specialty drug management

    Specialty endocrine and other high‑cost drugs are covered when ALL of the following are met:

    Formulary inclusion and tier: The specialty endocrine product is listed on the Drug List with a tier designation (e.g., P, NP, NP+, P+).

    Examples include ACTHAR, CRENESSITY, GENOTROPIN and other specialty endocrine agents.

    Prior authorization and specialty routing: If Requirements/Limits include 'PA' and/or 'SP', prior authorization must be obtained and the product must be dispensed via specialty pharmacy when indicated.

    CRENESSITY lists PA, QL and SP; ACTHAR lists PA and SP as examples.

    Quantity limits followed when listed: Any QL associated with the specialty product must be respected (e.g., CRENESSITY QL values).

    CRENESSITY capsule QL (60 capsules/30 days) and oral solution QL (120 mls/30 days) are shown in the formulary.

    Formulary inclusion with utilization controls

    Formulary inclusion and utilization control rules:

    Listed product attributes: Each product included in the formulary excerpt carries attributes: Drug Tier, and, where shown, Requirements/Limits (PA, QL, SP, ST, AC). Coverage is determined per these attributes and the member's plan.

    Prescribers must follow listed PA, QL and SP controls to secure coverage; tiering affects member cost-share.

    Product-level coverage controls

    Product‑level coverage controls — apply to each listed product line item:

    Drug Tier and special requirements: Each drug entry indicates a Drug Tier and may include Requirements/Limits such as PA, QL, SP, ST or AC which govern coverage and dispensing.

    Providers must obtain PA and adhere to QL/SP where indicated for each product.

    Coverage conditional on PA/QL/ST flags

    Per‑product controls — coverage conditional on listed attributes:

    ref":"b0_11","title":"Per-product coverage controls"},{
    citations":["252","255","256"],"intro":"Coverage for listed products is conditional on fulfilling the flagged requirements:","nodes":["{\"operator\":\"all\",\"n\":0,\"label\":\"Requirement flags govern coverage\",\"text\":\"Coverage is subject to the presence of requirement flags shown with each product: PA (prior authorization), QL (quantity limit), SP (specialty pharmacy), ST (step therapy) and AC (administrative criteria).\",\"threshold\":\"\",\"note\":\"Providers must submit PA requests and supporting documentation and adhere to QL/SP/ST as listed. Failure to meet these flags may result in claim denial.\"}"] ,"ref":"b0_12","title":"Coverage conditional on PA/QL/ST flags"}]}]},
    final_response_ok":true}]},
    title_missing_error":false}

    Drugs not listed on the payer's Drug List are not covered under the pharmacy benefit; coverage applies only to products that appear on the published drug list and are consistent with the member's benefit plan. In addition, the formulary excludes certain categories of products: compounded medications, repackaged medications, and drugs that have not received FDA approval are not covered under the pharmacy benefit. Members and providers should confirm coverage and tier placement at MyPrime.com or via the number on the member ID card.

    The provided excerpts do not define any standalone, explicit exclusion clauses for individual products; instead they present formulary line items with assigned Drug Tier and associated administrative flags (e.g., PA, QL, SP, AC). Where an entry lacks a specific exclusion statement, coverage is governed by the product's tier and any listed Requirements/Limits.

    This excerpt contains product listings with utilization controls but does not present explicit per-product exclusion language. Coverage determination for each listed product is informed by its Drug Tier and any Requirements/Limits shown (for example, entries listing PA or QL), rather than by separate stated exclusions in these chunks.

    Some formulary lines in this segment show the Requirements/Limits field as blank (displayed as '.'), which indicates that no specific utilization restriction (such as PA, QL, or SP) is listed for that particular presentation in the excerpt. Absence of a Requirements/Limits entry in the excerpt does not guarantee unrestricted coverage; providers should verify the current status on the official drug list.

    The document fragments do not list explicit clinical exclusion criteria. Instead, contraceptive, progestin and thyroid product entries (and others) display product-level Requirements/Limits (for example, AC, PA, QL) that govern coverage and dispensing. If clinical exclusions apply, they are not stated in these chunks and must be determined from plan-specific criteria or authorizations.

    Within these excerpts there are no explicit exclusion conditions recorded; the content consists of formulary line items (drug names, tiers) and occasionally shows Requirements/Limits as blank or with administrative flags. Any formal clinical exclusion rules are not present in this portion of the document.

    This segment lists drug products together with utilization controls such as PA, QL, and SP where applicable, but it does not include explicit clinical exclusion language. For listed products, coverage is conditioned on meeting any applicable Requirements/Limits shown next to the product.

    The formulary listings in this fragment define coverage in terms of Drug Tier and any associated administrative flags (for example, PA, QL, SP). They do not set out standalone clinical medical necessity rules within the excerpt; providers should follow the Requirements/Limits shown per product when seeking coverage.

    No specific exclusions for individual products appear in this excerpt. Instead, specialty biologics and other high-cost agents are listed with explicit utilization controls (for example, SKYRIZI and TREMFYA show PA and QL and are designated SP), indicating that coverage is contingent on meeting those controls rather than reflecting explicit per-product exclusions in these chunks.

    Drugs used solely for cosmetic purposes are identified as potentially not covered by the pharmacy benefit; the source lists hair growth agents (e.g., Propecia) as an example of a cosmetic indication that may be excluded from coverage under the pharmacy benefit.

    The extracts provided do not contain any entries explicitly labeled as 'Not Medically Necessary.' Across these chunks, the document shows formulary tiers and Requirements/Limits (such as AC, PA, QL), but it does not mark any products in these excerpts with a formal 'not medically necessary' determination.

    No statements explicitly declaring products as 'not medically necessary' appear in these chunks. Contraceptive and progestin lines show administrative controls and quantity limits (for example, many combined oral contraceptives list AC and QL (28 tablets/21 days)), but not 'not medically necessary' language in this excerpt.

    This portion of the extract does not include any 'not medically necessary' declarations. It provides thyroid and endocrine product listings with tiers and, where applicable, Requirements/Limits (often blank in the excerpt), but no explicit 'not medically necessary' statements are present here.

    These chunks do not contain explicit 'Not Medically Necessary' statements for the listed products. Instead, they show product-level utilization controls (for example, PA, QL, SP) that determine coverage conditions; absence of 'not medically necessary' language in the excerpt means such determinations are not provided here.

    Across these formulary fragments there are no explicit entries labeled 'Not Medically Necessary.' The listings focus on tier placement and utilization management flags (for example, PA, QL, SP) rather than labeling products as not medically necessary in the provided excerpts.

    Formulary listings and code tables

    Formulary drug list (sample entries)mixed
    AMOXICILLINamoxicillin (trihydrate) various forms and strengths listed
    AMOXICILLIN/CLAVULANATEamoxicillin & k clavulanate various formulations (susp, tabs, ER)
    CEFACLORcefaclor cap 250 mg, 500 mg
    CEFPODOXIMEcefpodoxime proxetil tab 100 mg, 200 mg
    AZITHROMYCINazithromycin susp and tablets; QL examples
    FIDAXOMICIN (DIFICID)fidaxomicin tab 200 mg; susp 40 mg/ml
    DOXYCYCLINEdoxycycline hyclate and monohydrate various forms
    BAXDELA (delafloxacin)delafloxacin meglumine tab 450 mg; QL noted
    CIPROFLOXACINciprofloxacin oral susp and tablets
    LEVOFLOXACINlevofloxacin oral solution and tablets
    1–10 of 17
    1/2
    Formulary product lines (partial)mixed
    DOVATOdolutegravir sodium-lamivudine tab 50-300 mg (base eq)
    EDURANTrilpivirine hcl tab 25 mg (base equivalent)
    efavirenzefavirenz tab 600 mg (Sustiva)
    emtricitabineemtricitabine caps 200 mg (Emtriva)
    EPCLUSAsofosbuvir-velpatasvir tab 200-50 mg, 400-100 mg
    EFAVIRENZILAMIVUDINEITENOefavirenz-lamivudine-tenofovir df tab 400-300-300 mg
    Formulary product lines (partial)mixed
    GENVOYAelvitegrav-cobic-emtricitab-tenofov af tab 150-150-200-10 mg
    HARVONIledipasvir-sofosbuvir tab 45-200 mg; 90-400 mg
    ISENTRESSraltegravir potassium tab/packet/chew formulations
    JULUCAdolutegravir sodium-rilpivirine hcl tab 50-25 mg
    LIVTENCITYmaribavir tab 200 mg
    MAVYRETglecaprevir-pibrentasvir tab 100-40 mg
    Formulary product lines (partial)mixed
    PAXLOVIDnirmatrelvir + ritonavir pack (multiple pack sizes)
    PREVYMISletermovir tab/pellet pack
    PREZISTAdarunavir formulations (tabs, oral suspension)
    RIBAVIRINribavirin cap/tab 200 mg
    Formulary product lines (partial)mixed
    SOVALDIsofosbuvir tab 200 mg, 400 mg
    STRIBILDelvitegrav-cobic-emtricitab-tenofovdf tab 150-150-200-300 mg
    SUNLENCAlenacapavir sodium tab and therapy packs
    SYMTUZAdarunavir-cobic-emtricitab-tenofov af tab 800-150-200-10 mg
    VIREADtenofovir disoproxil fumarate formulations
    Formulary product lines (partial)mixed
    SOLOSECsecnidazole granules packet 2 gm
    CAYSTONaztreonam lysine for inhalation solution 75 mg
    XIFAXANrifaximin tab 200 mg, 550 mg
    VANCOMYCINvancomycin oral capsule/solution formulations (Vancocin, Firvanq)
    Vaccine product linesmixed
    COMIRNATYCOVID-19 mRNA vaccine (2024-25) 30 mcg/0.3 ml
    ABRYSVORSV pre-fusion vaccine recomb for IM
    AREXVYRSV pref3 vaccine recomb adjuvanted for IM
    BEXSEROmeningococcal B vaccine (recombinant)
    CAPVAXIVEpneumococcal 21-valent conjugate vaccine
    Formulary drug entries (no billing codes in this section)mixed
    N/ANo CPT/HCPCS/ICD codes provided in this excerpt; entries are drug product names with tiers and requirements.
    Drug listing (no billing codes)mixed
    no CPT/HCPCS/ICD codes listedThis section contains NDC-like product listings, tiers, and utilization controls but does not list procedure or diagnosis codes.
    Selected listed products (partial)mixed
    GLASSIA 1000 mg/50 mlalpha1-proteinase inhibitor (human) inj 1000 mg/50ml
    GLASSIA 4 g/200 ml; 5 g/250 mlalpha1-proteinase inhibitor (human) iv soln 4 gm/200ml, 5 gm/250ml
    KALYDECO 150 mg tabivacaftor tab 150 mg
    KALYDECO packetsivacaftor packet 5.8 mg, 13.4 mg, 25 mg, 50 mg, 75 mg
    OFEV 100 mg; 150 mg capnintedanib esylate cap 100 mg, 150 mg
    Acid suppression agentsmixed
    PRILOSEC packets 2.5 mg; 10 mgomeprazole magnesium for delayed release susp packet 2.5 mg; 10 mg
    VOQUEZNA 10 mg; 20 mgvonoprazan fumarate tab 10 mg, 20 mg
    Pancreatic enzyme replacementsmixed
    CREON multiple strengthspancrelipase DR cap various unit strengths
    ZENPEP multiple strengthspancrelipase DR cap various unit strengths
    NDC/CPT/HCPCS not provided — formulary drug entriesmixed
    No codes listed
    Common quantity limits — examples
    30 tablets/30 daysCommon short-course oral tablet QL (example)
    60 tablets/30 daysHigher monthly tablet QL for select products
    90 tablets/30 daysExtended monthly tablet QL used for some chronic therapies
    1 kit/30 daysKit-based QL (e.g., infusion/titration kits) per 30 days
    4 bottles/30 daysLiquid formulation QL example (bottles per 30 days)
    Insulin volume limit
    Insulin volume limitQL (100 mls/30 days)
    Applies to rapid‑acting, short‑acting, basal and pen/cartridge formatsMultiple insulin presentations list QL (100 mls/30 days)
    Provider actionPrescriptions should not exceed 100 mls per 30 days without prior authorization or override
    Oral contraceptive tablet limit
    Oral contraceptive tablet limitQL (28 tablets/21 days)
    Applies to many combined oral contraceptivesMultiple product entries list AC and QL (28 tablets/21 days)
    Ring/device alternativesSome ring/devices have different QLs (e.g., 1 ring/365 days) noted separately
    Emergency/OTC levonorgestrel limit
    Emergency/OTC levonorgestrel limitQL (2 tablets/365 days)
    Coverage noteELLA and levonorgestrel products listed with AC/PA/QL as applicable; OTC emergency levonorgestrel limited to 2 tablets per year
    Provider actionDocument indication when requesting coverage beyond QL
    Common oral antidiabetic quantity limits
    Common oral antidiabetic QLQL (30 tablets/30 days) or QL (120 tablets/30 days) depending on product
    ExamplesFARXIGA, GLYXAMBI, JARDIANCE often listed with QL (30 tablets/30 days)
    Injectable GLP‑1/GIP notesSome GLP‑1/GIP agents have pen/pack QLs (e.g., 4 pens/28 days; 1 pen/28 days) distinct from oral tablet QLs

    Prior authorization, step therapy, documentation and denial risks

    Prior Authorization

    Prior Authorization Requirement

    Prior Authorization Required — Many medications in this Drug List require prior authorization (PA) before coverage. Items noted with “PA” in the Special Requirements/Requirements/Limits column must have an approved prior authorization request on file or the claim may be denied.

    • Prescribers must submit PA requests and receive approval prior to dispensing PA-marked drugs.
    • Claims submitted without required PA or missing documentation may be denied.
    • PA status often accompanies QL (quantity limits), SP (specialty pharmacy routing), and AC (authorization criteria) — confirm all applicable flags when requesting coverage.
    Prior Authorization

    Prior authorization required for select agents

    Prior authorization is specifically required for a range of select agents across categories — examples found in the Drug List include certain inhaled antibiotics, antifungals, antivirals/hepatitis agents, oncology and specialty drugs, endocrine and metabolic agents, GI specialty agents, biologics and vaccines.

    • Antimicrobials/antifungals: TOBRAMYCIN nebu soln (PA, QL, SP); POSACONAZOLE (PA); VORICONAZOLE (PA).
    • Antivirals/Hepatitis: EPCLUSA, MAVYRET, VOSEVI, many HCV and HIV products listed with PA and QL.
    • Oncology/specialty oral agents and injectables: numerous oral targeted therapies and immunotherapies (examples: ABIRATERONE, IBRUTINIB, PALBOCICLIB, VENETOCLAX, many with PA, QL, SP).
    • Endocrine/specialty agents: select agents (e.g., ACTHAR, OMNITROPE, SKYTROFA, MYALEPT) show PA and/or SP requirements.
    • GI specialty: VOWST and other specialty GI products show PA and QL flags.
    Prior Authorization

    Prior authorization required for select antivirals/hepatitis agents

    Prior authorization triggers for antivirals/hepatitis agents — many direct-acting antivirals and select antiviral products are managed with PA, QL and sometimes SP. Examples in the list: EPCLUSA (PA, QL, SP), MAVYRET (PA, QL, SP), VOSEVI (PA, QL, SP), and other HIV/HBV/HCV agents noted with PA.

    • When EPCLUSA, MAVYRET, VOSEVI or similar agents are prescribed, submit PA documentation consistent with antiviral coverage criteria and pack/quantity selection.
    • Some antiviral products are handled via specialty pharmacy (SP) — confirm routing and supply limits when submitting PA.
    Prior Authorization

    Prior authorization required for select oncology/specialty drugs

    Prior authorization required for oncology and specialty drugs — Many oral and injectable oncology agents and other specialty therapies are labeled PA and frequently combined with QL and SP. Prescribers must submit PA requests with clinical documentation supporting medical necessity and dosing.

    • Examples: ABIRATERONE, IBRUTINIB, IMBRUVICA formulations, TAGRISSO, VENCLEXTA, PALBOCICLIB, many others show PA + QL + SP.
    • Oral oncology agents often have specific QL (e.g., 30/30, 60/30) and pack-based QLs; ensure PA cites the intended pack/dose.
    Prior Authorization

    Prior authorization required for PA-marked drugs

    PA-marked drugs across the Drug List require prior authorization — many products in the document are explicitly marked PA. Review Special Requirements/Requirements/Limits columns and submit PA where indicated to avoid claim denials.

    • PA indicators appear next to product lines (e.g., “Requirements/Limits = PA”).
    • Some entries include combined flags like “PA, QL, SP” or “AC, PA, QL”; include documentation addressing all listed controls in the PA request.
    Prior Authorization

    Prior authorization required for listed products

    Prior authorization required for products listed with PA, and for many other listed products — the Drug List includes many PA-flagged items across therapeutic classes; verify PA requirements for each item before dispensing.

    • Check the Special Requirements/Requirements/Limits column for PA on every drug line.
    • Some plans may impose additional PA requirements not shown in this consolidated list — always confirm with the member’s benefit plan.
    Prior Authorization

    PA required for selected endocrine/specialty drugs

    PA required for selected endocrine and specialty drugs — multiple endocrine, metabolic and rare-disease agents are PA- or SP-managed. Examples include ACTHAR, OMNITROPE, JYNARQUE, SKYTROFA, SOMAVERT, MYALEPT and others shown with PA and SP.

    • These products frequently require specialty pharmacy routing (SP) and may have pack- or vial-based QLs — document dose, indication, and quantity used in the PA submission.
    • Prescribers should reference product-specific criteria (e.g., prior approvals for growth hormone, corticotropin) when completing PA forms.
    Prior Authorization

    Prior authorization required for many GI specialty drugs

    PA requirement for many GI specialty drugs — Several GI specialty products (e.g., VOWST, VIBERZI, TREMFYA interactions in GI-immunology overlap) are managed with PA, QL and sometimes SP; verify flags for each product line.

    • VOWST (fecal microbiota spores) is listed with PA and QL (12 capsules/12 months) and SP — submit clinical rationale for use.
    • TREMFYA and SKYRIZI biologic entries include PA and QL; induction packs and maintenance supplies may have different QLs (example: TREMFYA induction pack QL 3 kits/180 days).
    Prior Authorization

    Prior authorization required for specified specialty drugs

    Prior authorization is required for numerous specified specialty drugs (biologics, injectables and kits). Many biologic products list PA plus quantity limits and specialty routing; follow the PA process and specialty pharmacy routing instructions.

    • Examples: SKYRIZI (PA, QL, SP), TREMFYA (PA, QL, SP, induction pack QL), ZYMFENTRA (PA, QL, SP).
    • ZYMFENTRA kit/syringe presentations include specific QLs (2 kits/28 days or 2 syringes/28 days) — ensure PA addresses the exact presentation being requested.
    Prior Authorization

    Prior Authorization Triggers and Specialty Product Handling

    Prior authorization triggers & specialty product handling — PA flags, SP routing and QL indicators are common triggers for administrative review and specialty handling. Products marked SP may require specialty pharmacy fulfillment or referral.

    • When a product is marked SP, coordinate with the payer’s specialty pharmacy or follow prior authorization instructions to route benefit appropriately.
    • PA triggers include the presence of PA in the Requirements/Limits column and often accompany QL or SP flags.
    Prior Authorization

    Prior authorization and quantity limit enforcement

    Prior authorization and quantity limit enforcement — Many products are managed by combined utilization controls (PA + QL). Claims that exceed QL or lack PA/AC may be denied. Providers should document and support any requests to exceed stated QLs.

    • Quantity limits are shown per product (e.g., 30 tablets/30 days, 4 pens/28 days, pack/180 days) — verify the exact QL when submitting PA.
    • Prescriptions exceeding listed QLs require supporting documentation and will generally need an approved PA to be covered.
    Denial Risk

    Prior authorization / administrative controls and denial risk

    Prior authorization, administrative controls and denial risk — Failure to obtain required PA/AC or to follow SP routing or QL limits can lead to claim denial. Administrative flags (PA, AC, SP, QL) indicate controls that must be satisfied for coverage.

    • AC (authorization/criteria) entries require submission of supporting documentation per payer process.
    • Claims submitted without required PA or exceeding QL may be denied and members may be financially responsible if dispensed without coverage.
    Documentation Required

    Document QL/PA when submitting (Documentation requirements)

    Document QL/PA/AC when submitting — Include clear documentation of requested quantity, dosing, indication, prior treatment history, and any specialty routing required. For AC-listed products, provide the documentation specified by the payer’s authorization process.

    • For QL exceedance requests include rationale and expected duration of therapy.
    • For AC or PA items, attach relevant clinical notes, prior medication trials, laboratory or diagnostic results that meet the payer’s criteria.
    • TREMFYA and similar biologics: when ordering induction kits vs maintenance supplies, document pack/kit needs and submit PA with QL justification (e.g., TREMFYA induction pack QL 3 kits/180 days).
    Documentation Required

    Provide supporting documentation for PA and QL

    Documentation to support PA — Prescribers must provide clinical justification for medical necessity, prior therapy history (when step therapy applies), dosing and pack/quantity selection, and any lab or diagnostic evidence required by the payer.

    • Liquid formulations and oral solutions often have specific QLs (examples: enalapril oral soln QL 1200 mls/30 days; KALYDECO packets QL 60 packets/30 days) — include dosing and supply rationale.
    • Provide dosing schedule and expected duration when requesting PA for induction packs or starter kits (e.g., TREMFYA induction pack documentation).
    • If step therapy (ST) or step rules apply, document prior trials and failures of required preferred alternatives.
    Documentation Required

    TREMFYA PA documentation (induction vs maintenance)

    TREMFYA and similar biologic PA documentation — Induction packs and maintenance presentations often have discrete QLs and require PA. Submit documentation that specifies kit vs maintenance dosing and supports the requested supply (e.g., induction pack QL 3 kits/180 days).

    • TREMFYA induction pack: Requirements/Limits show PA and QL (3 kits/180 days) — indicate induction schedule and justification in the PA request.
    • Confirm whether the request is for an induction pack or routine maintenance dosing and supply; document accordingly.
    Step Therapy

    Step Therapy Requirement and Specialty/Step Rules

    Step therapy (ST) and specialty/step rules — Some products are subject to step therapy (ST) or specialty program (SP) requirements. ST flags indicate a requirement to try specified alternatives before a non-preferred agent will be covered.

    • If an ST flag is present, include documentation of prior trials and outcomes of required step agents when submitting PA or exception requests.
    • Some agents are marked ST but specific algorithms may not be listed in this consolidated document — check the member’s benefit plan for exact step requirements.
    Step Therapy

    Supply and step restrictions (Step therapy / supply)

    Step therapy specifics and supply/step restrictions — Where supply limits or QLs are listed together with ST or SP (for example GLP-1/GLP‑1 receptor agonists showing QL 4 pens/28 days), ensure PA or exception requests document adherence to supply rules or justify exceptions.

    • GLP-1/GIP agents (e.g., MOUNJARO, OZEMPIC, ZEPBOUND) often have PA and QL flags including pen/28-day or pens/180-day limits — include supply needs and prior therapy history.
    • When step therapy is not specified in this fragment but an ST flag is present, verify the plan-level step requirements before submitting an exception.

    Step therapy flags and program notes

    ProgramIndicator in formularyNotes for providers
    Step therapy programs
    Marked with 'ST' in the Special Requirements column of the drug list
    Plan-specific details apply; members may need to try a specified alternative before coverage. Refer to member benefit materials for exact step requirements.
    Drug groupFormulary flagsProvider action
    Selected high-cost antivirals (e.g., EPCLUSA, MAVYRET, SOVALDI)
    PA, QL, SP noted for many hepatitis C direct-acting antivirals
    Submit prior authorization and, where indicated, route through specialty pharmacy prior to coverage; adhere to listed QL (e.g., 30 tablets/30 days).
    SummaryStep therapy sequences provided?Implication
    Extracted formulary segments
    No explicit step therapy sequences provided in these chunks
    Coverage listings show flags (PA, QL, SP); where ST is required it will be shown next to the product — consult benefit materials for the actual step sequence.
    Drug categoryRequirements notedProvider action
    Oncology and specialty oral agents (examples: abiraterone, brigatinib, others)
    Many entries list PA and sometimes QL and SP; some may be subject to specialty program or step requirements
    Prescribers must submit prior authorization where shown; specialty routing may be required and step/plan program rules (if any) must be followed per benefit plan.
    Drug examplesFormulary flags / limitsProvider note
    TRULICITY (dulaglutide)
    PA; QL example listed: 4 pens/28 days
    Obtain prior authorization and adhere to supply limits when prescribing (QL shown on formulary).
    Drug typeFormulary flagsRouting requirement
    Specialty drugs and select high-cost agents
    Often require PA and are labeled SP in the Requirements/Limits column
    These products are typically dispensed via the plan's specialty pharmacy; providers must obtain PA and use SP channel as indicated.
    FlagMeaningStep therapy detail available?
    SP
    Indicates specialty pharmacy fulfillment required
    Specific step therapy sequences are not provided in this fragment — see benefit documents for plan-level step details.
    Product examplesFlags in formularyProvider implication
    Selected specialty agents (e.g., REPATHA, UPTRAVI, TYVASO)
    Often shown as SP with PA and/or QL prior to coverage
    Providers must obtain PA and route prescriptions to specialty pharmacy when indicated; QL must be observed. Step edits are not listed in the extract.
    Agent / packFormulary designationStep-therapy details
    UPTRAVI TITRATION PACK
    Listed as a titration pack with Requirements/Limits = PA, QL (pack/180 days), SP
    Titration packs are listed, but explicit step-therapy failure rules are not provided in the document fragments.
    Step therapy presenceNotes foundAction
    Step therapy rules not detailed
    Some products designated 'SP' or have tiering which may imply specialty routing; ST flags appear on select lines elsewhere but no general ST algorithms are present in this fragment
    Follow PA/QL/SP indications on each product line; consult plan materials for any ST program specifics.
    ProductsFormulary flagsStep therapy status
    Aripiprazole formulations; CAPLYTA; certain clozapine entries
    Shown with QL and some lines display 'ST' in Special Requirements
    These selected products are marked ST indicating step edits apply; prescribers must document trials/failures of preferred alternatives when required.
    ExamplesFlags observedProvider requirement
    FANAPT, RISPERIDONE ODT, VERSACLOZ
    Listed with ST flags (and QL where applicable)
    When ST is flagged, prescribers should document prior trials and failures of preferred agents per plan requirements at claim or PA review.
    ContextFormulary indicationCoverage implication
    Non-preferred formulations and certain branded products
    Some non-preferred or alternate formulations are subject to ST prior to coverage (ST flag present)
    Providers must document attempted or failed therapies with preferred products when ST is indicated; consult the formulary line for exact expectations.

    Common quantity limits (QL) and product examples

    Unspecified / typical day supply
    Typical day supplyTypically 30‑day supply; some plans allow 90‑day for maintenance medications
    Plan variationSpecific day‑supply allowances may vary by member benefit plan
    Reference for current limitsSee MyPrime.com or bcbstx.com for the most up‑to‑date drug list and limits
    Azithromycin tablet quantity limit
    Azithromycin (certain strengths)QL (60 tablets/180 days)
    Formulation noteApplies to specified tablet strengths as listed in formulary entries
    Provider actionPrescriptions should conform to the 60 tablets/180 days limit unless override obtained
    BAXDELA (delafloxacin) quantity limit
    BAXDELA delafloxacin 450 mgQL (28 tablets/180 days)
    Tier/requirementListed with Drug Tier = NP and QL as shown
    Provider actionAdhere to 28 tablets/180 days limit or seek prior authorization if clinically needed
    ARIKAYCE quantity limit
    ARIKAYCE amikacin liposome inhalationQL (235.2 mls/28 days)
    RequirementsProduct entries include PA and SP designations where applicable
    DispensingSpecialty handling and QL apply to inhaled specialty antibiotics
    TOBI PODHALER quantity limit
    TOBI PODHALER tobramycin inhalation capsulesQL (224 capsules/56 days)
    Specialty designationListed with SP and QL in formulary entries
    Provider actionEnsure dispensing matches 224 capsules per 56 days or obtain prior authorization
    EPCLUSA quantity limits
    EPCLUSA (sofosbuvir‑velpatasvir)QL (30 tablets/30 days) (tablet pack) or QL (28 tablets/28 days) (pellet pack)
    Requirement flagsEPCLUSA lines include PA and SP where indicated
    Provider actionPrescribe the appropriate pack type and quantity consistent with the listed QL
    General quantity‑limit patterns
    General QL formatsQuantity limits vary by product — examples: 30/30, 60/30, 90/30, 1 kit/30 days, 4 bottles/30 days
    Per‑product specificationEach formulary line lists the exact QL for that product presentation
    Provider actionRefer to specific product entry for exact QL when prescribing or submitting PA
    EMTRIVA quantity limit
    EMTRIVA (emtricitabine oral solution)QL (720 mls/30 days)
    Formulation noteApplies to EMTRIVA 10 mg/ml oral solution as listed
    Provider actionPrescriptions for oral solution should not exceed 720 mL per 30 days without authorization
    ISENTRESS (chewable) quantity limit
    ISENTRESS chewableQL (180 tablets/30 days)
    Formulation noteChewable formulation QL specified separately from other presentations
    Provider actionOrder chewable tablet quantity consistent with 180 tablets/30 days limit
    Abiraterone acetate quantity limit
    Abiraterone acetateQL (60 tablets/30 days) where specified
    RequirementSome formulations include PA and SP flags in addition to QL
    Provider actionConfirm exact QL on the product line when submitting authorization
    AUGTYRO quantity limits
    AUGTYRO (repotrectinib)QL (30 or 60 capsules/30 days) depending on strength
    Strength‑dependent limitsDifferent capsule strengths have different monthly QLs as listed
    Provider actionSpecify strength when requesting PA or dispensing to match the QL
    BOSULIF quantity limits
    BOSULIF (bosutinib)QL values listed per formulation (examples: 150 capsules/30 days; 90 tablets/30 days; 30 tablets/30 days)
    Formulation‑specificQL varies by capsule vs tablet strength and formulation
    Provider actionRefer to listed formulation QL when prescribing or submitting PA
    Erlotinib 25 mg quantity limit
    Erlotinib HCl tab 25 mgQL (60 tablets/30 days)
    Formulation noteNamed strength example — other strengths may have different QLs
    Provider actionUse the specific strength line when documenting QL for PA/claims
    GOMEKLI quantity limit
    GOMEKLI (mirdametinib)QL (168 capsules/28 days)
    Alternate QL shownSome strengths list QL (84 capsules/28 days) for other pack sizes
    Provider actionConfirm capsule count and days (28 days) on the product entry when requesting PA
    LYNPARZA quantity limit
    LYNPARZA (olaparib)QL (120 tablets/30 days)
    Specialty routingOften listed with SP and PA alongside the QL
    Provider actionDocument tablet quantity consistent with 120 tablets/30 days for PA/claims
    TAGRISSO quantity limit
    TAGRISSO (osimertinib)QL (30 tablets/30 days)
    RequirementProduct entries include PA and SP flags where applicable
    Provider actionPrescribe within 30 tablets per 30 days unless PA obtained for higher quantity
    RUBRACA quantity limit
    RUBRACA (rucaparib)QL (120 tablets)
    Provider actionAdhere to 120‑tablet QL as listed or seek PA for exceptions
    Specialty flagOften listed with PA and SP in formulary entries
    RYDAPT quantity limit
    RYDAPT (midostaurin)QL (240 capsules)
    Provider actionDispense per 240‑capsule QL unless prior authorization indicates otherwise
    Specialty routingListed with PA and SP for many strengths
    STIVARGA quantity limit
    STIVARGA (regorafenib)QL (84 tablets)
    TimeframeQL specified for 28‑day period in formulary entry
    Provider actionUse the listed QL when requesting PA or submitting claims
    VENCLEXTA quantity limits (examples)
    VENCLEXTA (venetoclax) 10 mgQL (60 tablets)
    VENCLEXTA 50 mgQL (30 tablets)
    VENCLEXTA 100 mgQL (180 tablets)

    Additional QL product examples

    Common oral corticosteroid quantity limit
    Common oral corticosteroidsQL (90 tablets)
    ExamplesIncludes prednisone, prednisolone, methylprednisolone listings with 90‑tablet QL
    Provider actionAdhere to 90‑tablet QL or supply supporting documentation for excess
    Topical testosterone gel quantity limits
    Topical testosterone gelsQL (150–300 grams)
    Formulation specificsDifferent gel presentations list either 150 g or 300 g per 30 days depending on product
    Provider actionPrescriptions must match the grams/month QL or require PA for larger amounts
    Transdermal estradiol patch limit
    Transdermal estradiol patchesQL (30 patches)
    Applies to multiple patch brandsClimara, Menostar and similar listed with QL (30 patches/30 days)
    Provider actionConfirm patch QL on product line when prescribing replacement supplies
    Contraceptive rings/devices quantity limits
    Contraceptive rings/devicesQL (1 ring/365 days) or standard QL per product
    ExamplesANNOVERA listed with AC and QL (1 ring/365 days); NuvaRing and similar devices follow product‑specific QLs
    Provider actionFollow the yearly ring QL or supply documentation for exceptions
    Combined oral contraceptives quantity limit
    Combined oral contraceptivesQL (28 tablets)
    Typical dispensingMost combined oral contraceptives list AC and QL (28 tablets/21 days) or QL (28 tablets)
    Provider actionPrescribe 28‑tablet packs consistent with QL or request exception per plan
    ELLA (ulipristal) quantity limit
    ELLA (ulipristal acetate 30 mg)QL (2 tablets)
    TimeframeQL applies per 365 days (2 tablets/365 days)
    Provider actionDocument indication for ELLA if requesting coverage beyond the 2‑tablet annual QL
    Common oral antidiabetic quantity limit (examples)
    FARXIGA / GLYXAMBI / JARDIANCE (oral antidiabetics)QL (30 tablets)
    Formulary noteMany oral antidiabetics list a 30‑tablet monthly QL
    Provider actionPrescribe within 30 tablets/30 days or request PA for additional supply
    GLP‑1 / GIP injectable supply examples
    MOUNJARO / TRULICITY / OZEMPIC (injectables)Supply varies — examples: 4 pens/28 days or 1 pen/28 days depending on product/strength
    Formulary flagsMany GLP‑1/GIP injectables include PA and SP and specify pen limits per timeframe
    Provider actionConfirm pen count and timeframe per product line when submitting authorization
    Rapid‑acting insulin quantity limit
    Rapid‑acting insulins (FIASP, HUMALOG, NOVOLOG, LYUMJEV)QL (100 mls/30 days)
    Applies to pens/cartridges/vialsPen and cartridge formats commonly use the 100 mL/30 days QL
    Provider actionEnsure dispensing aligns with 100 mL monthly QL or request PA for larger volumes
    Insulin product quantity limit (general)
    Many insulin productsCommon QL listed as 100 mls/30 days across rapid, short and basal insulins
    ReferenceApplies broadly to multiple insulin brands and presentations in the formulary extract
    Provider actionFollow listed insulin QL or submit PA/documentation for exceptions
    CRENESSITY quantity limits
    CRENESSITY (crinecerfont)QL (60 capsules/30 days) and QL (120 mls/30 days) for oral solution
    Formulation noteCapsule and oral solution formulations have distinct QLs listed
    Provider actionSpecify formulation when requesting authorization or dispensing
    GALAFOLD quantity limit
    GALAFOLD (migalastat)QL (14 capsules/28 days)
    Timeframe28‑day capsule QL as listed in formulary entries
    Provider actionPrescribe per 14 capsules/28 days or document need for exception
    GENOTROPIN cartridge quantity limit
    GENOTROPIN cartridgesQL (15 cartridges/30 days) — PA and SP noted for some strengths
    Formulary noteCartridge QL applies to specified strengths (5 mg; 12 mg entries referenced)
    Provider actionPA and specialty routing may apply in addition to the QL
    MENOPUR quantity limit
    MENOPURQL (60 vials/30 days)
    Specialty handlingListed with SP and QL in formulary entries
    Provider actionAdhere to 60 vials/30 days limit or provide documentation for exceptions
    OVIDREL quantity limit
    OVIDRELQL (2 syringes/30 days)
    Formulary noteOvidrel listed with QL and specialty designation for fertility use
    Provider actionRequest PA if supply beyond 2 syringes per 30 days is clinically necessary

    Where drugs are covered (medical vs pharmacy vs specialty)

    Note
    Note
    Note
    Note
    Note
    Note

    Terms and abbreviations used in the formulary

    Specialty drugs (definition and characteristics)
    Specialty drugs — definitionMedications used to treat serious or complex conditions; may require special handling and can be self‑administered or administered by a health care professional
    Coverage implicationMedically administered specialty drugs may be covered under the medical benefit rather than pharmacy
    Reference for current listFor a current list of specialty medications visit MyPrime.com or bcbstx.com
    QL — Quantity Limit definition
    QL — Quantity Limit definitionMaximum quantity allowed in a specified timeframe shown as 'QL' (e.g., '60 tablets/180 days')
    UsageAppears in the Special Requirements column next to product presentations
    Provider actionProviders must adhere to listed QLs or submit supporting documentation/PA for exceptions
    PA — Prior Authorization definition
    PA — Prior Authorization definitionCoverage requires approval prior to dispensing; indicated with 'PA' next to the product
    ConsequenceClaims may be denied if PA is not obtained when required
    Provider actionSubmit required documentation through the payer's prior authorization process
    SP — Specialty Pharmacy definition
    SP — Specialty Pharmacy definitionProduct designated for specialty management and fulfillment; may require dispensing through specialty pharmacy channel
    ImplicationSP designation may require specialty pharmacy routing and triggers additional handling/PA
    Provider actionUse specialty pharmacy channel when indicated and follow SP requirements on formulary entry
    QL — example formats and usage
    QL — example formatsFormats shown include 'X tablets/30 days', 'Y capsules/28 days', 'Z mls/30 days' and kit/pack limits
    Insulin exampleQL (100 mls/30 days) commonly used for insulin products
    Multi‑formatLimits apply to tablets, capsules, mL, kits, packs and pens as specified per product
    PA — illustrative examples
    PA — example usePA appears on high‑cost antivirals/antifungals (e.g., EPCLUSA, Noxafil) and specialty inhaled agents (e.g., ARIKAYCE)
    Denial riskClaims may be denied if PA not obtained prior to dispensing for PA‑flagged products
    Provider actionSubmit PA with required supporting documentation per payer instructions
    SP — illustrative examples
    SP — illustrative examplesSP appears on many hepatitis/antiviral agents and specialty biologics (e.g., EPCLUSA, HARVONI, MAVYRET)
    ImplicationSP designation may require specialty pharmacy dispensing and coordination
    Provider actionRefer to specialty pharmacy channel for SP‑designated products
    AC — Administrative Coverage / Access Code
    AC — Administrative Coverage indicatorIndicates Authorization/Criteria applies; used for vaccines and some contraceptives (shown as 'AC' in Requirements/Limits)
    ImplicationAC flags mean coverage is subject to additional documentation or criteria
    Provider actionProvide required documentation per payer process when AC is listed
    AC — meaning and examples
    AC indicates authorization/criteria appliesUsed in Requirements/Limits fields to show administrative controls apply
    ExamplesVaccines such as COMIRNATY, AFLURIA show Requirements/Limits = AC
    Provider actionFollow authorization process for AC‑flagged products
    PA — indicator and implications
    PA flag meaningIndicates Prior Authorization is required for coverage
    Clinical impactMany oncology and specialty oral agents list PA as a requirement
    Provider actionObtain PA before dispensing to avoid claim denial
    QL — indicator and implications
    QL flag meaningIndicates a Quantity Limit is applied; the exact limit is listed alongside product presentation
    ExamplesCommon insulin QL: 100 mls/30 days; tablets often 30/30, 60/30, 90/30
    Provider actionPrescriptions and PA requests must reflect the stated QL to be covered
    SP — Specialty program indicator
    SP flag meaningIndicates Specialty program applies — product managed through specialty pharmacy
    ImplicationSP may require specific dispensing channel, PA and additional documentation
    Provider actionCoordinate with specialty pharmacy for fulfillment when SP is listed

    Context and scope

    Specialty drugs are medications used to treat complex or serious conditions and often require special handling or patient support services. They can be oral, topical, or injectable and may be administered by the member (self-administered) or by a health care professional. When a specialty medication is administered by a health care professional it may be covered under the medical benefit rather than the pharmacy benefit; specialty products in the formulary are commonly identified with the SP (specialty) designation and may require prior authorization and specialty pharmacy routing.

    Policy revision timeline